Pursuing Deeper Responses With Linvoseltamab in Newly Diagnosed Multiple Myeloma Patients image

Pursuing Deeper Responses With Linvoseltamab in Newly Diagnosed Multiple Myeloma Patients

Oct 07, 2024
02:00PM - 03:00PM EDT
Online Event
Overview

This webinar will focus on how linvoseltamab, might be used to achieve deeper treatment responses for newly diagnosed myeloma patients who do not reach MRD (minimal residual disease) negativity after initial therapy. We will discuss how this strategy may delay the need for a transplant while offering patients more effective long-term control of their disease. Dr. Kazandjian and Kellye, APRN from the University of Miami Sylvester Comprehensive Cancer Center will join us to discuss this exciting new research.

Highlights
Agenda
2:00 PM
Introductions
Cynthia Cahoon, RN

Cynthia introduces the agenda of the event and featured speakers Dickran Kazandjian, MD & Kellye Koubek, MS, APRN, AGNP-C

2:05 PM
Presentation
Dr. Kazandjian and Kellye Koubek

Dr. Kazandjian and Kellye Koubek share about Linvoseltamab for newly diagnosed patients

2:35 PM
Questions and Answers
Audience

Type your questions in the chat and we will answer them! 

Speakers & Moderators
Healthtree contact Cynthia Cahoon, RN

Cynthia Cahoon, RN

Cynthia is a newborn ICU nurse by trade that has spent the last six years in the medical device industry educating nurses and doctors about devices that are new to their facility. In her spare time she enjoys hiking, traveling the world with her family, and creating Halloween animatronics for her annual front yard display. She has a passion for life-long learning and enjoys sharing what she learns with the people around her.
Healthtree contact Dickran Kazandjian, MD

Dickran Kazandjian, MD

Dr. Kazandjian’s clinical and translational research interests lie in the treatment of precursor plasma cell disorders including high risk smoldering multiple myeloma and the role of immunotherapy in plasma cell dyscrasias. In addition, he is re-evaluating the role of autologous stem cell transplant (ASCT) in the era of highly efficacious novel-novel drugs, immunotherapy biologics, and cell-based therapies with the hypothesis that certain subsets of patients with myeloma may not benefit by default upfront ASCT.
Healthtree contact Kellye Koubek, MS, APRN, AGNP-C

Kellye Koubek, MS, APRN, AGNP-C

Kellye Koubek is an Advanced Practice Registered Nurse at the University of Miami’s Sylvester Comprehensive Cancer Center.  After graduating in 2011 with a Bachelor of Science in Nursing from Xavier University, Kellye Koubek gained valuable experience working as a registered nurse in various hospital platforms. She then pursued a Master of Science from Hunter College in New York City, graduating in 2021 from Hunter’s Adult-Gerontology Primary Care Nurse Practitioner program. Her commitment to advancing oncology research is underscored by her prior experience as a Clinical Trial Nurse at Memorial Sloan Kettering Cancer Center. Currently, Kellye serves as a Research Advanced Practice Nurse at the Sylvester Myeloma Institute, specializing in plasma cell disorders. Beyond her clinical duties, Kellye actively contributes to the advancement of medical science by serving as a sub-investigator for interventional clinical trials, playing a crucial role in the implementation and development of research trials, and facilitating the dissemination of clinical trial findings.